US approval for darunavir (TMC-114, Prezista)
3 August 2006. Related: Antiretrovirals.
Antiretrovirals
Boehringer stops tipranavir trial in treatment-naive patients
3 August 2006. Related: Antiretrovirals.
FDA approves fixed-dose combination of efavirenz/tenofovir/FTC (Atripla): joint company collaboration produces once-daily one pill combination
3 August 2006. Related: Antiretrovirals.
Evidence that CCR5 is protective against West Nile virus: implications for CCR5 inhibitors
3 August 2006. Related: Antiretrovirals.
Efavirenz levels above recommended upper target in 20% of African patients in Senegal
11 June 2006. Related: Conference reports, Antiretrovirals.
Lower dose of AZT provides adequate exposure in patients with low body weight
11 June 2006. Related: Conference reports, Antiretrovirals.
Fixed-dose formulation of efavirenz/tenofovir/FTC bioequivalent to separate dosing
10 June 2006. Related: Conference reports, Antiretrovirals.
Saquinavir/r (1000/100mg) levels reduced when taken fasted and should be taken with food
10 June 2006. Related: Conference reports, Antiretrovirals.
Lack of food effect with Meltrex formulation of lopinavir/r
10 June 2006. Related: Conference reports, Antiretrovirals.
Food interaction reduces ddI intracellular absorption and supports requirement to take fasted
10 June 2006. Related: Conference reports, Antiretrovirals.
Conflicting results on how T-20 affects tipranavir
10 June 2006. Related: Conference reports, Antiretrovirals.
Development of d-d4FC (dexelvucitabine, Reverset) discontinued
12 May 2006. Related: Antiretrovirals.
Other new antiretrovirals at Denver: the future seems bright
12 April 2006. Related: Conference reports, Antiretrovirals.
Early integrase inhibitor studies in treatment experienced patients raise hopes for new drugs in a new class
25 March 2006. Related: Conference reports, Antiretrovirals.
Atazanavir in treatment naive patients, with and without ritonavir boosting
25 March 2006. Related: Conference reports, Antiretrovirals.
CNS penetration of ARV drugs is associated with lower CSF viral load
25 March 2006. Related: Conference reports, Antiretrovirals.
Metrex formulation of Kaletra available on named patient access in UK
10 March 2006. Related: Antiretrovirals.
Treatment-naive trial of tipranavir discontinues highest dose arm
8 March 2006. Related: Antiretrovirals.
FTC studies at EACS: reduced incidence of M184V compared to 3TC; side effect profile in clinical practice
11 February 2006. Related: Conference reports, Antiretrovirals.
Efficacy of lopinavir/r in patients with advanced HIV (CD4 <25 cells/mm3)
11 February 2006. Related: Conference reports, Antiretrovirals.
Potential barriers to use of T-20: results from patient and physician interviews
11 February 2006. Related: Conference reports, Antiretrovirals.
Clinical experience of switching to atazanavir in the UKs largest clinic
11 February 2006. Related: Conference reports, Antiretrovirals.
Replacing a PI with atazanavir: separating swans from ducklings?
11 February 2006. Related: Conference reports, Antiretrovirals.
TMC 125: some good and bad news
11 February 2006. Related: Conference reports, Antiretrovirals.
When to change a failing regimen: second-line and salvage strategies
11 February 2006. Related: Conference reports, Antiretrovirals.
Antiretrovirals and other stuff!
11 February 2006. Related: Conference reports, Antiretrovirals.
Understanding TMC114 power against resistant HIV
10 February 2006. Related: Conference reports, Antiretrovirals.
New antiretroviral compounds at ICAAC: new PI brecanavir from GSK; maturation inhibitor PA-457; antiviral activity of monoclonal antibody; TNX-355 in treatment experienced patients
10 February 2006. Related: Conference reports, Antiretrovirals.
Three measures confirm 144-week renal record of tenofovir
10 February 2006. Related: Conference reports, Antiretrovirals.
Low rash risk with efavirenz after nevirapine rash
10 February 2006. Related: Conference reports, Antiretrovirals.
SMART study halted due to safety concerns with significantly more AIDS events in the treatment interruption arm
9 February 2006. Related: Antiretrovirals.
TMC114 (darunavir) new drug applications submitted to US and European regulatory agencies
9 February 2006. Related: Antiretrovirals.
Named-patient access programme available in UK for new protease inhibitor darunavir (TMC114)
13 December 2005. Related: Antiretrovirals.
Tibotec discontinues TMC125 study C227: phase III studies continue
13 December 2005. Related: Antiretrovirals.
New Kaletra tablet formulation (meltrex) approved by FDA
13 December 2005. Related: Antiretrovirals.
GSK closes phase 3 studies of its CCR5 inhibitor aplaviroc and terminates development programme
13 December 2005. Related: Antiretrovirals.
Schering discontinues phase 2 studies of vicriviroc in treatment naive patients
13 December 2005. Related: Antiretrovirals.
FDA issues approvable letter for Bioject needle-free injection device
13 December 2005. Related: Antiretrovirals.
Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM)
13 December 2005. Related: Antiretrovirals, Treatment strategies.
GSK stops trials of CCR5 entry inhibitor GW873140 in naive patients
13 October 2005. Related: Antiretrovirals.
AZT comes off patent: generic versions approved for US market
13 October 2005. Related: Antiretrovirals.
Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results
14 September 2005. Related: Conference reports, Antiretrovirals.
Strategies for salvage therapy
14 September 2005. Related: Conference reports, Antiretrovirals.
Antiviral activity of foscarnet in salvage patients
14 September 2005. Related: Conference reports, Antiretrovirals.
Novel strategies with existing drugs
14 September 2005. Related: Conference reports, Antiretrovirals.
Antiretroviral activity of new and novel agents
14 September 2005. Related: Conference reports, Antiretrovirals.
FDA filing of T-20 sNDA for administration with a needle-free injection device
14 August 2005. Related: Antiretrovirals.
Reduced replicative capacity of M184V explains benefit of 3TC monotherapy compared to stopping all drugs
14 July 2005. Related: Conference reports, Antiretrovirals.
TMC-114 to be submitted for registration based on Phase 2b trial results: expanded access expected in UK in Autumn 2005
14 July 2005. Related: Antiretrovirals.
Tipranavir (Aptivus) approved in US
14 July 2005. Related: Antiretrovirals.
FDA fast track designation for CCR5 inhibitor vicriviroc (SCH-D)
14 July 2005. Related: Antiretrovirals.
Pfizer discontinues development of capravirine
14 July 2005. Related: Antiretrovirals.
Effect of age on lopinavir concentrations
15 June 2005. Related: Conference reports, Antiretrovirals.
Gender and pharmacokinetics of saquinavir
15 June 2005. Related: Conference reports, Antiretrovirals.
Responses to atazanavir, Kaletra and side effects
15 June 2005. Related: Conference reports, Antiretrovirals.
500mg saquinavir (Invirase) approved in Europe
15 June 2005. Related: Antiretrovirals.
Roche to withdraw saquinavir soft gel caps (Fortovase)
15 June 2005. Related: Antiretrovirals.
FDA approve lopinavir/r once daily for treatment naive patients
15 June 2005. Related: Antiretrovirals.
Safety data for tenofovir updated
15 June 2005. Related: Antiretrovirals.
FDA approve entecavir for HBV
15 June 2005. Related: Antiretrovirals.
Efavirenz warning in pregnancy strengthened
15 June 2005. Related: Antiretrovirals.
New ritonavir interactions
15 June 2005. Related: Antiretrovirals.
FDA advisory committee recommends approval for tipranavir – material from hearing online
15 June 2005. Related: Antiretrovirals.
Application for meltrex formulation of Kaletra submitted to the FDA
15 June 2005. Related: Antiretrovirals.
24-week efficacy of TMC114 in PI-experienced patients
18 April 2005. Related: Conference reports, Antiretrovirals.